Am J Cardiol. 1985 Nov 22;56(14):3G-9G.
The effects of early intervention with metoprolol in patients with suspected or definite acute myocardial infarction (AMI) have been assessed in a randomized, double-blind, placebo-controlled international study. Patients aged 75 years or younger were eligible for entry if they presented to a coronary care unit within 24 hours of the onset of symptoms of an AMI. Exclusion criteria included current treatment with a beta blocker or calcium-channel blocker, heart rate less than or equal to 65 beats/min, systolic blood pressure less than or equal to 105 mm Hg, contraindications and other administrative reasons. Treatment began with an intravenous loading dose (3 X 5 mg injections of metoprolol or placebo at 2-minute intervals) followed by an oral regime of 200-mg metoprolol daily or placebo. The study period was 15 days in addition to the day of randomization. The patients' clinical history and status at entry were documented. The following outcome variables were recorded: mortality, development of AMI, serum enzyme activity, electrocardiographic signs of AMI, late or recurrent AMI, arrhythmias, treatment of chest pain, concomitant treatment, adverse events and details of treatment with trial medication.
在一项随机、双盲、安慰剂对照的国际研究中，已评估了美托洛尔对疑似或确诊急性心肌梗死（AMI）患者进行早期干预的效果。75岁及以下的患者如果在AMI症状发作后24小时内就诊于冠心病监护病房，则有资格入选。排除标准包括目前正在接受β受体阻滞剂或钙通道阻滞剂治疗、心率小于或等于65次/分钟、收缩压小于或等于105毫米汞柱、存在禁忌证以及其他管理方面的原因。治疗开始时先静脉给予负荷剂量（每隔2分钟注射3次5毫克美托洛尔或安慰剂），随后每日口服200毫克美托洛尔或安慰剂。除随机分组当天外，研究期为15天。记录了患者入组时的临床病史和状况。记录了以下结局变量：死亡率、AMI的发生、血清酶活性、AMI的心电图征象、晚期或复发性AMI、心律失常、胸痛治疗情况、伴随治疗、不良事件以及试验用药的治疗细节。
